Argenx Posts First Operating Profit on Surging VYVGART Sales and Expanding Autoimmune Pipeline

Argenx Se ( (ARGX) ) has shared an update.

On February 26, 2026, Argenx reported that 2025 marked its first year of operating profitability, delivering $4.2 billion in global product net sales, up 90% year over year, and $1.1 billion in operating income, driven by rapid uptake of VYVGART and expansion to about 19,000 patients worldwide. The company also highlighted positive Phase 3 ADAPT OCULUS data in ocular myasthenia gravis, ongoing regulatory review for seronegative generalized MG, and a broad late-stage pipeline that is expected to yield four Phase 3 molecules and multiple new clinical candidates by the end of 2026, underpinning its Vision 2030 growth strategy and reinforcing its leadership in FcRn‑based therapies.

Argenx outlined a series of upcoming milestones, including planned label expansions for VYVGART into ocular MG and additional MG populations, registrational studies in rheumatology and Graves’ disease, and Phase 3 programs for empasiprubart in MMN and CIDP and adimanebart in congenital myasthenic syndromes. While discontinuing adimanebart development in ALS following Phase 2a data, the company is advancing next‑generation FcRn assets, autoinjector delivery, and several first‑in‑class molecules, positioning the business for sustained growth and deeper penetration of autoimmune markets over the next several years.

The most recent analyst rating on (ARGX) stock is a Buy with a $1008.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Spark’s Take on ARGX Stock

According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.

Argenx Se’s strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company’s robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.

To see Spark’s full report on ARGX stock, click here.

More about Argenx Se

Argenx SE is a global immunology company focused on developing and commercializing antibody-based therapies for severe autoimmune diseases. Its lead product, VYVGART, an FcRn-targeting biologic, is approved for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and primary immune thrombocytopenia in select markets, with a growing pipeline across neuromuscular, hematologic and rheumatologic indications.

Average Trading Volume: 343,746

Technical Sentiment Signal: Buy

Current Market Cap: $51.91B

Find detailed analytics on ARGX stock on TipRanks’ Stock Analysis page.